State Street’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-8,070
| Closed | -$86.5K | – | 4474 |
|
|
2023
Q4 | $86.5K | Hold |
8,070
| – | – | ﹤0.01% | 4078 |
|
|
2023
Q3 | $49K | Hold |
8,070
| – | – | ﹤0.01% | 4295 |
|
|
2023
Q2 | $55.7K | Hold |
8,070
| – | – | ﹤0.01% | 4392 |
|
|
2023
Q1 | $127K | Hold |
8,070
| – | – | ﹤0.01% | 4246 |
|
|
2022
Q4 | $161K | Hold |
8,070
| – | – | ﹤0.01% | 4193 |
|
|
2022
Q3 | $144K | Sell |
8,070
-2,255
| -22% | -$48.4K | ﹤0.01% | 4284 |
|
|
2022
Q2 | $229K | Sell |
10,325
-32,919
| -76% | -$734K | ﹤0.01% | 4137 |
|
|
2022
Q1 | $1.2M | Buy |
43,244
+266
| +0.6% | +$9.68K | ﹤0.01% | 3748 |
|
|
2021
Q4 | $1.95M | Buy |
42,978
+2,596
| +6% | +$175K | ﹤0.01% | 3642 |
|
|
2021
Q3 | $3.37M | Buy |
40,382
+3,822
| +10% | +$316K | ﹤0.01% | 3435 |
|
|
2021
Q2 | $3.47M | Buy |
36,560
+35,594
| +3,685% | +$4.22M | ﹤0.01% | 3399 |
|
|
2021
Q1 | $161K | Buy |
966
+70
| +8% | +$9.26K | ﹤0.01% | 3861 |
|
|
2020
Q4 | $88K | Hold |
896
| – | – | ﹤0.01% | 3817 |
|
|
2020
Q3 | $30K | Sell |
896
-175
| -16% | -$8.58K | ﹤0.01% | 3786 |
|
|
2020
Q2 | $61K | Sell |
1,071
-94
| -8% | -$5.3K | ﹤0.01% | 3695 |
|
|
2020
Q1 | $68K | Hold |
1,165
| – | – | ﹤0.01% | 3643 |
|
|
2019
Q4 | $92K | Sell |
1,165
-176
| -13% | -$18.2K | ﹤0.01% | 3686 |
|
|
2019
Q3 | $134K | Sell |
1,341
-9
| -0.7% | -$921 | ﹤0.01% | 3643 |
|
|
2019
Q2 | $180K | Sell |
1,350
-782
| -37% | -$121K | ﹤0.01% | 3620 |
|
|
2019
Q1 | $358K | Sell |
2,132
-522
| -20% | -$77.9K | ﹤0.01% | 3493 |
|
|
2018
Q4 | $290K | Buy |
2,654
+2,088
| +369% | +$418K | ﹤0.01% | 3515 |
|
|
2018
Q3 | $123K | Buy |
566
+21
| +4% | +$50.4K | ﹤0.01% | 3635 |
|
|
2018
Q2 | $1.17M | Buy |
+545
| New | +$1.38M | ﹤0.01% | 3383 |
|
|
2016
Q4 | – | Sell |
-15
| Closed | -$16K | – | 3695 |
|
|
2016
Q3 | $16K | Hold |
15
| – | – | ﹤0.01% | 3545 |
|
|
2016
Q2 | $11K | Hold |
15
| – | – | ﹤0.01% | 3699 |
|
|
2016
Q1 | $10K | Hold |
15
| – | – | ﹤0.01% | 3703 |
|
|
2015
Q4 | $15K | Hold |
15
| – | – | ﹤0.01% | 3670 |
|
|
2015
Q3 | $15K | Hold |
15
| – | – | ﹤0.01% | 3677 |
|
|
2015
Q2 | $30K | Hold |
15
| – | – | ﹤0.01% | 3644 |
|
|
2015
Q1 | $14K | Sell |
15
-2
| -12% | -$1.99K | ﹤0.01% | 3650 |
|
|
2014
Q4 | $17K | Sell |
17
-1
| -6% | -$893 | ﹤0.01% | 3658 |
|
|
2014
Q3 | $19K | Sell |
18
-3
| -14% | -$4.42K | ﹤0.01% | 3646 |
|
|
2014
Q2 | $41K | Sell |
21
-250
| -92% | -$495K | ﹤0.01% | 3563 |
|
|
2014
Q1 | $580K | Buy |
271
+2
| +0.7% | +$4.98K | ﹤0.01% | 3345 |
|
|
2013
Q4 | $621K | Sell |
269
-40
| -13% | -$91.5K | ﹤0.01% | 3326 |
|
|
2013
Q3 | $863K | Sell |
309
-53
| -15% | -$264K | ﹤0.01% | 3271 |
|
|
2013
Q2 | $3.35M | Buy |
+362
| New | +$2.79M | ﹤0.01% | 2685 |
|
Other funds holding ONCT
QPW
RB
BJL
State Street's ONCT Position: Q1 2024 in Review
State Street sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 8,070 shares — an estimated $86.5K sold.
State Street first reported a position in ONCT in Q2 2013 and held it in 37 quarters. The position peaked at $3.47M in Q2 2021. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.
- State Street reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- State Street sold 8,070 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $86.5K.
- State Street first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 37 quarters.
- State Street's Oncternal Therapeutics, Inc. Common Stock position peaked at $3.47M in Q2 2021.
- 24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.
Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.